NCT02072486View on ClinicalTrials.gov

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 18, 2013

Primary Completion Date

July 19, 2019

Study Completion Date

July 19, 2020

Conditions
Advanced Adult Hepatocellular CarcinomaLocalized Non-Resectable Adult Hepatocellular CarcinomaStage III Childhood Hepatocellular CarcinomaStage IIIA Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaStage IIIC Hepatocellular CarcinomaStage IV Childhood Hepatocellular CarcinomaStage IVA Hepatocellular CarcinomaStage IVB Hepatocellular Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER

NCT02072486 - Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter